Parliament Workbench
Data: Motions & questions to 19 Nov 2026 · Votes to 12 Nov 2026

Members' Business Motion · S4M-15568 · Session 4

Access to Duchenne Muscular Dystrophy Treatment, Translarna

Lodged by Jackie Baillie Lab Lodged 3 Feb 2016 12 supporters Cross-party support

The motion

That the Parliament recognises that Translarna, a new treatment for Duchenne muscular dystrophy, is being assessed by the Scottish Medicines Consortium; understands that there have been powerful patient and family testimonies in the patient and clinician engagement process about the importance of access to Translarna; acknowledges the need for the assessment to take into account the impact of Duchenne muscular dystrophy as the condition progresses; understands that one boy in East Lothian affected by Duchenne muscular dystrophy has access to Translarna through an individual patient treatment request, and notes people's hopes that Translarna will be available to all boys with Duchenne who are eligible for the treatment after the Scottish Medicines Consortium completes its assessment.

Signatures by party

12 MSPs besides the lodger · 4 from other parties
Lab 8Con 3SNP 1

Party on the day each MSP signed. Signing a motion is voluntary and not whipped. Who signs whose motions

Vote

No recorded vote on this motion. Most motions are never debated, and many that are debated are agreed without a division. Vote records are published from 2011.

Supporters

12 MSPs

Lab 8 Con 3 SNP 1

Show all 12 supporters by party

Lab 8

Con 3

SNP 1

Party shown is each supporter’s party when the motion was published.

In the Official Report

No contribution in the Official Report cites S4M-15568 by reference.